The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Treatment of toxoplasmosis: Current options and future perspectives
Open accessAbstract
Toxoplasmosis is a worldwide parasitic disease infecting about one third of humans, with possible severe outcomes in neonates and immunocompromised patients. Despite continuous and successful efforts to improve diagnosis, therapeutic schemes have barely evolved since many years. This article aims at reviewing the main clinical trials and current treatment practices, and at addressing future perspectives in the light of ongoing researches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global burden of congenital toxoplasmosis: a systematic review
Torgerson, P. R., & Mastroiacovo, P. (2013) · Bulletin of the World Health Organization · doi:10.2471/blt.12.111732 · Cited by 748 · cited 1×
“000 annual cases (Torgerson and Mastroiacovo, 2013), with long-term neurological sequelae and/or visual impairment possibly expected in infected untreated children.”
Background
Research works printed but not linked: 146
- Adeyemi, 2018, Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents, Parasitol. Res., 117, 355, 10.1007/s00436-017-5698-1 · doi:10.1007/s00436-017-5698-1
- Adriaensen, 2018, Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients, Front. Immunol., 8, 10.3389/fimmu.2017.01943 · DOI
- Afifi, 2015, The immunomodulatory effects of rolipram abolish drug-resistant latent phase of Toxoplasma gondii infection in a murine model, J. Microsc. Ultrastruct., 3, 86, 10.1016/j.jmau.2014.12.001 · DOI
- Alday, 2017, Drugs in development for toxoplasmosis: advances, challenges, and current status, Drug Des. Devel. Ther., 11, 273, 10.2147/DDDT.S60973 · DOI · Paper page
- Arens, 2007, Treating AIDS-associated cerebral toxoplasmosis - pyrimethamine plus sulfadiazine compared with cotrimoxazole, and outcome with adjunctive glucocorticoids, S. Afr. Med. J., 97, 956
- Baatz, 2006, Reactivation of Toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient, Ocul. Immunol. Inflamm., 14, 185, 10.1080/09273940600659740 · doi:10.1080/09273940600659740
- Bahrami, 2015, Potential application of nanochitosan film as a therapeutic agent against cutaneous leishmaniasis caused by L. major, Parasitol. Res., 114, 4617, 10.1007/s00436-015-4707-5 · doi:10.1007/s00436-015-4707-5
- Ben-Harari, 2017, Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review, Drugs in R&D, 17, 523, 10.1007/s40268-017-0206-8 · DOI · Paper page
- Benmerzouga, 2015, Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis, Antimicrob. Agents Chemother., 59, 6939, 10.1128/AAC.01683-15 · DOI
- Bhadra, 2010, Absence of both IL-7 and IL-15 severely impairs the development of CD8 T cell response against Toxoplasma gondii, PLoS One, 5, 10.1371/journal.pone.0010842 · DOI
- Bhadra, 2011, The CD8 T-cell road to immunotherapy of toxoplasmosis, Immunotherapy, 3, 789, 10.2217/imt.11.68 · DOI
- Bhadra, 2011, Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade, Proc. Natl. Acad. Sci. U. S. A., 108, 9196, 10.1073/pnas.1015298108 · DOI · Paper page
- Bhadra, 2012, PD-1–mediated attrition of polyfunctional memory CD8+ T cells in chronic Toxoplasma infection, J. Infect. Dis., 206, 125, 10.1093/infdis/jis304 · DOI
- Bhadra, 2013, ‘Donor CD8 + T cells prevent Toxoplasma gondii de-encystation but fail to rescue the exhausted endogenous CD8 + T cell population’, Infection and Immunity, Edited by J. L. Flynn, 81, 3414
- Bosch-Driessen, 2002, A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis, Am J. Ophthalmol., 134, 34, 10.1016/S0002-9394(02)01537-4 · doi:10.1016/s0002-9394(02)01537-4
- Bougdour, 2009, Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites, J. Exp. Med., 206, 953, 10.1084/jem.20082826 · DOI · Paper page
- Boyom, 2014, Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica, Antimicrob. Agents Chemother., 58, 5848, 10.1128/AAC.02541-14 · DOI
- Butler, 2013, Ocular toxoplasmosis II: clinical features, pathology and management, Clin. Exp. Ophthalmol., 41, 95, 10.1111/j.1442-9071.2012.02838.x · doi:10.1111/j.1442-9071.2012.02838.x
- Cai, 2000, Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii, Infect. Immun., 68, 6932, 10.1128/IAI.68.12.6932-6938.2000 · DOI · Paper page
- Campbell, 2006, First case of toxoplasmosis following small bowel transplantation and systematic review of tissue-invasive toxoplasmosis following noncardiac solid organ transplantation, Transplantation, 81, 408, 10.1097/01.tp.0000188183.49025.d5 · doi:10.1097/01.tp.0000188183.49025.d5
- Cha, 2001, Effects of specific monoclonal antibodies to dense granular proteins on the invasion of Toxoplasma gondii in vitro and in vivo, Korean J. Parasitol., 39, 233, 10.3347/kjp.2001.39.3.233 · DOI
- Chirgwin, 2002, Clin. Infect. Dis., 34, 1243, 10.1086/339551 · doi:10.1086/339551
- Chung, 2008, Bilateral Toxoplasma Retinochoroiditis simulating cytomegalovirus retinitis in an allogeneic bone marrow transplant patient, Korean J. Ophthalmol., 22, 197, 10.3341/kjo.2008.22.3.197 · doi:10.3341/kjo.2008.22.3.197
- Cortina-Borja, 2010, Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study, PLoS Med., 7, 10.1371/journal.pmed.1000351 · DOI · Paper page
- Daffos, 1988, Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis, N. Engl. J. Med., 318, 271, 10.1056/NEJM198802043180502 · DOI
- Dannemann, 1992, Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California collaborative treatment group, Ann. Intern. Med., 116, 33, 10.7326/0003-4819-116-1-33 · DOI · Paper page
- de Kock, 2018, Population pharmacokinetic properties of sulfadoxine and pyrimethamine: a pooled analysis to inform optimal dosing in African children with uncomplicated malaria, Antimicrob. Agents Chemother., 62, 10.1128/AAC.01370-17 · DOI
- Deckert-Schlüter, 1997, Interleukin-10 downregulates the intracerebral immune response in chronic Toxoplasma encephalitis, J. Neuroimmunol., 76, 167, 10.1016/S0165-5728(97)00047-7 · DOI
- Desmonts, 1974, Toxoplasmosis in pregnancy and its transmission to the fetus, Bull. N. Y. Acad. Med., 50, 146
- Dhakal, 2018, Toxoplasmosis in the non-orthotopic heart transplant recipient population, how common is it? Any indication for prophylaxis?, Curr. Opin. Organ Transplant., 23, 407, 10.1097/MOT.0000000000000550 · doi:10.1097/mot.0000000000000550
- Dittmar, A. J., Drozda, A. A. and Blader, I. J. (2016) ‘Drug repurposing screening identifies novel compounds that effectively inhibit Toxoplasma gondii growth’, mSphere, 1(2). doi:https://doi.org/10.1128/mSphere.00042-15. · DOI
- Djurković-Djaković, 1999, Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis, Antimicrob. Agents Chemother., 43, 2240, 10.1128/AAC.43.9.2240 · doi:10.1128/aac.43.9.2240
- Djurković-Djaković, 2002, Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii, J. Antimicrob. Chemother., 50, 981, 10.1093/jac/dkf251 · doi:10.1093/jac/dkf251
- Docampo, 1978, Lipid peroxidation and the generation of free radicals, superoxide anion, and hydrogen peroxide in beta-lapachone-treated Trypanosoma cruzi epimastigotes, Arch. Biochem. Biophys., 186, 292, 10.1016/0003-9861(78)90438-1 · DOI
- Doggett, 2012, Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis, Proc. Natl. Acad. Sci. U. S. A., 109, 15936, 10.1073/pnas.1208069109 · DOI · Paper page
- Doggett, 2014, Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection, Antimicrob. Agents Chemother., 58, 3547, 10.1128/AAC.01823-13 · DOI
- Doliwa, 2013, Identification of differentially expressed proteins in sulfadiazine resistant and sensitive strains of toxoplasma gondii using difference-gel electrophoresis (DIGE), Int. J. Parasitol., 3, 35
- Dunay, 2009, Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model, Antimicrob. Agents Chemother., 53, 4450, 10.1128/AAC.00502-09 · doi:10.1128/aac.00502-09
- Dunay, 2018, Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice, Clin. Microbiol. Rev., 31
- Eissa, 2015, Could miltefosine be used as a therapy for toxoplasmosis?, Exp. Parasitol., 157, 12, 10.1016/j.exppara.2015.06.005 · DOI
- El-Zawawy, 2015, Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii, Acta Trop., 141, 103, 10.1016/j.actatropica.2014.09.020 · DOI
- El-Zawawy, 2015, Triclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosis, Exp. Parasitol., 149, 54, 10.1016/j.exppara.2014.12.007 · DOI
- Escotte-Binet, 2018, Metallopeptidases of Toxoplasma gondii: in silico identification and gene expression, Parasite, 25, 26, 10.1051/parasite/2018025 · DOI
- Etewa, 2018, Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice, J. Parasit. Dis., 42, 102, 10.1007/s12639-017-0973-8 · DOI
- Ferguson, 1994, An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii, Int. J. Exp. Pathol., 75, 111
- Fernàndez-Sabé, 2012, Risk factors, clinical features, and outcomes of toxoplasmosis in solid-organ transplant recipients: a matched case-control study, Clin. Infect. Dis., 54, 355, 10.1093/cid/cir806 · doi:10.1093/cid/cir806
- Ferreira, 2002, Activity of natural and synthetic naphthoquinones against Toxoplasma gondii, in vitro and in murine models of infection, Parasite, 9, 261, 10.1051/parasite/2002093261 · doi:10.1051/parasite/2002093261
- Ferreira, 2006, Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1′-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine, Exp. Parasitol., 113, 125, 10.1016/j.exppara.2005.12.006 · doi:10.1016/j.exppara.2005.12.006
- Ferreira, 2012, New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains, Exp. Parasitol., 132, 450, 10.1016/j.exppara.2012.09.003 · doi:10.1016/j.exppara.2012.09.003
- Foulon, 1999, Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters, Am. J. Obstet. Gynecol., 181, 843, 10.1016/S0002-9378(99)70311-X · doi:10.1016/s0002-9378(99)70311-x
- Freeman, 2008, Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study, Pediatrics, 121, e1215, 10.1542/peds.2007-2169 · doi:10.1542/peds.2007-2169
- Fu, 2011, Generation of a neutralizing human monoclonal antibody fab fragment to surface antigen 1 of Toxoplasma gondii tachyzoites, Infect. Immun., 79, 512, 10.1128/IAI.00969-10 · doi:10.1128/iai.00969-10
- Fung, 1996, Treatment regimens for patients with toxoplasmic encephalitis, Clin. Ther., 18, 1037, 10.1016/S0149-2918(96)80059-2 · doi:10.1016/s0149-2918(96)80059-2
- Gajurel, 2015, Toxoplasma prophylaxis in haematopoietic cell transplant recipients: a review of the literature and recommendations, Curr. Opin. Infect. Dis., 28, 283, 10.1097/QCO.0000000000000169 · doi:10.1097/qco.0000000000000169
- Gallant, 2015, Get rich quick with old generic drugs! The Pyrimethamine pricing scandal, Open Forum Infect. Dis., 2, 10.1093/ofid/ofv177 · DOI
- Gallino, 1996, Toxoplasmosis in heart transplant recipients, Eur. J. Clin. Microbiol. Infect. Dis., 15, 389, 10.1007/BF01690095 · doi:10.1007/bf01690095
- Gazzinelli, 1993, Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts, Proc. Natl. Acad. Sci. U. S. A., 90, 6115, 10.1073/pnas.90.13.6115 · DOI · Paper page
- Gazzinelli, 1996, In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha, J. Immunol., 157, 798, 10.4049/jimmunol.157.2.798 · DOI · Paper page
- Gilbert, 2003, Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii, BJOG, 110, 112, 10.1046/j.1471-0528.2003.02325.x · DOI
- Goswami, 2015, Alternative treatment approach to cerebral toxoplasmosis in HIV/AIDS: experience from a resource-poor setting, Int. J. STD AIDS, 26, 864, 10.1177/0956462414560594 · doi:10.1177/0956462414560594
- Gras, 2005, Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres, Acta Paediatr., 94, 1721, 10.1111/j.1651-2227.2005.tb01844.x · doi:10.1111/j.1651-2227.2005.tb01844.x
- Hegab, 2003, Immunopathogenesis of toxoplasmosis, Clin. Exp. Med., 3, 84, 10.1007/s10238-003-0011-2 · DOI
- Hernandez, 2017, A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option?, HIV Med., 18, 115, 10.1111/hiv.12402 · doi:10.1111/hiv.12402
- Holland, 2002, An update on current practices in the management of ocular toxoplasmosis, Am J. Ophthalmol., 134, 102, 10.1016/S0002-9394(02)01526-X · doi:10.1016/s0002-9394(02)01526-x
- Hotop, 2012, Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy, Clin. Infect. Dis., 54, 1545, 10.1093/cid/cis234 · doi:10.1093/cid/cis234
- Innes et al., 2019, A one health approach to vaccines against Toxoplasma gondii, Food Waterborne Parasitol.
- Jackowski, 1989, Acetoacetyl-acyl carrier protein synthase. A target for the antibiotic thiolactomycin, J. Biol. Chem., 264, 7624, 10.1016/S0021-9258(18)83280-X · DOI
- Jacobson, 2001, Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS, AIDS, 15, 583, 10.1097/00002030-200103300-00007 · doi:10.1097/00002030-200103300-00007
- Kadri, 2014, The potential of quinoline derivatives for the treatment of Toxoplasma gondii infection, Exp. Parasitol., 145, 135, 10.1016/j.exppara.2014.08.008 · DOI
- Kasagi, 2011, PD-1 and autoimmunity, Crit. Rev. Immunol., 31, 265, 10.1615/CritRevImmunol.v31.i4.10 · DOI
- Katlama, 1996, Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS, Clin. Infect. Dis., 22, 268, 10.1093/clinids/22.2.268 · DOI · Paper page
- Khan, 1996, IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice, J. Immunol., 157, 2103, 10.4049/jimmunol.157.5.2103 · DOI
- Khan, 1994, Interleukin-12 enhances murine survival against acute toxoplasmosis, Infect. Immun., 62, 1639, 10.1128/iai.62.5.1639-1642.1994 · DOI · Paper page
- Khan, 1995, IL-10 mediates immunosuppression following primary infection with Toxoplasma gondii in mice, Parasite Immunol., 17, 185, 10.1111/j.1365-3024.1995.tb00888.x · DOI
- Khan, 1999, Immune CD8(+) T cells prevent reactivation of Toxoplasma gondii infection in the immunocompromised host, Infect. Immun., 67, 5869, 10.1128/IAI.67.11.5869-5876.1999 · doi:10.1128/iai.67.11.5869-5876.1999
- Kieffer, 2008, Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis, Pediatr. Infect. Dis. J., 27, 27, 10.1097/INF.0b013e318134286d · doi:10.1097/inf.0b013e318134286d
- Kongsaengdao, 2008, Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients, J. Int. Assoc. Phys. AIDS Care, 7, 11
- Lai, 2012, Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections, Proc. Natl. Acad. Sci. U. S. A., 109, 14182, 10.1073/pnas.1208775109 · DOI
- Lebech, 1999, Feasibility of neonatal screening for Toxoplasma infection in the absence of prenatal treatment, Danish congenital toxoplasmosis study group’, Lancet, 353, 1834
- Lim, 2014, Recent advances in Toxoplasma gondii Immunotherapeutics, Korean J. Parasitol., 52, 581, 10.3347/kjp.2014.52.6.581 · DOI
- Lourido, 2010, Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma, Nature, 465, 359, 10.1038/nature09022 · DOI · Paper page
- Luft, 1993, Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome, N. Engl. J. Med., 329, 995, 10.1056/NEJM199309303291403 · DOI · Paper page
- Lykins, 2018, CSGID solves structures and identifies phenotypes for five enzymes in Toxoplasma gondii, Front. Cell. Infect. Microbiol., 8, 352, 10.3389/fcimb.2018.00352 · DOI
- Maldonado, 2017, Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States, Pediatrics, 139, 10.1542/peds.2016-3860 · DOI · Paper page
- Mandelbrot, 2018, Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial, Am. J. Obstet. Gynecol., 219, 386.e1, 10.1016/j.ajog.2018.05.031 · doi:10.1016/j.ajog.2018.05.031
- Martino, 2005, Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation, Clin. Infect. Dis., 40, 67, 10.1086/426447 · doi:10.1086/426447
- Martins-Duarte, 2009, Thiolactomycin analogues as potential anti-Toxoplasma gondii agents, Parasitol. Int., 58, 411, 10.1016/j.parint.2009.08.004 · DOI
- Maubon, 2010, Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds, Antimicrob. Agents Chemother., 54, 4843, 10.1128/AAC.00462-10 · DOI
- Mazumdar, 2006, Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondii, Proc. Natl. Acad. Sci. U. S. A., 103, 13192, 10.1073/pnas.0603391103 · DOI · Paper page
- McFadden, 2000, Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance, Mol. Biochem. Parasitol., 108, 1, 10.1016/S0166-6851(00)00184-5 · DOI · Paper page
- McFarland, 2016, Review of experimental compounds demonstrating anti-Toxoplasma activity, Antimicrob. Agents Chemother., 60, 7017, 10.1128/AAC.01176-16 · DOI
- McLeod, 2006, Outcome of treatment for congenital toxoplasmosis, 1981–2004: the national collaborative Chicago-based, congenital toxoplasmosis study, Clin. Infect. Dis., 42, 1383, 10.1086/501360 · DOI · Paper page
- McPhillie, 2016, New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections, Sci. Rep., 6, 10.1038/srep29179 · doi:10.1038/srep29179
- Mele, 2002, Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature, Bone Marrow Transplant., 29, 691, 10.1038/sj.bmt.1703425 · doi:10.1038/sj.bmt.1703425
- Meneceur, 2008, In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone, Antimicrob. Agents Chemother., 52, 1269, 10.1128/AAC.01203-07 · DOI
- Mets, 1996, Eye manifestations of congenital toxoplasmosis, Am J. Ophthalmol., 122, 309, 10.1016/S0002-9394(14)72057-4 · DOI · Paper page
- Montazeri, 2017, A systematic review of in vitro and in vivo activities of anti-Toxoplasma drugs and compounds (2006-2016), Front. Microbiol., 8, 25, 10.3389/fmicb.2017.00025 · DOI · Paper page
- Montoya, 2004, Toxoplasmosis, Lancet, 363, 1965, 10.1016/S0140-6736(04)16412-X · DOI · Paper page
- Mui, 2008, Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo, PLoS Negl. Trop. Dis., 2, e190, 10.1371/journal.pntd.0000190 · doi:10.1371/journal.pntd.0000190
- Müller, 2017, Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis, J. Antimicrob. Chemother., 72, 2334, 10.1093/jac/dkx134 · DOI
- Murata, 2017, Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites, PLoS One, 12, 10.1371/journal.pone.0178203 · DOI
- Ni Nyoman, 2013, Apoptosis-like cell death pathways in the unicellular parasite Toxoplasma gondii following treatment with apoptosis inducers and chemotherapeutic agents: a proof-of-concept study, Apoptosis, 18, 664, 10.1007/s10495-013-0832-8 · DOI
- O'Donnell, 2004, Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4), Trends Pharmacol. Sci., 25, 158, 10.1016/j.tips.2004.01.003 · DOI · Paper page
- Ojo, 2014, A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation, J. Infect. Dis., 209, 275, 10.1093/infdis/jit522 · DOI
- Opsenica, 2015, Tetraoxanes as inhibitors of apicomplexan parasites Plasmodium falciparum and Toxoplasma gondii and anti-cancer molecules, J. Serb. Chem. Soc., 80, 1339, 10.2298/JSC150430063O · doi:10.2298/jsc150430063o
- Ozgonul, 2017, Recent developments in the diagnosis and treatment of ocular toxoplasmosis, Ophthalmic Res., 57, 1, 10.1159/000449169 · DOI
- Patel, 1996, Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis, Radiology, 199, 433, 10.1148/radiology.199.2.8668790 · doi:10.1148/radiology.199.2.8668790
- Petersen, 2007, Prevention and treatment of congenital toxoplasmosis, Expert Rev. Anti-Infect. Ther., 5, 285, 10.1586/14787210.5.2.285 · doi:10.1586/14787210.5.2.285
- Peyron, 2017, Congenital toxoplasmosis in France and the United States: one parasite, two diverging approaches, PLoS Negl. Trop. Dis., 11, 10.1371/journal.pntd.0005222 · doi:10.1371/journal.pntd.0005222
- Pfaff, 2014, New clinical and experimental insights into Old World and neotropical ocular toxoplasmosis, Int. J. Parasitol., 44, 99, 10.1016/j.ijpara.2013.09.007 · DOI
- Phan, 2008, Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life, Am J. Ophthalmol., 146, 375, 10.1016/j.ajo.2008.04.033 · doi:10.1016/j.ajo.2008.04.033
- Prusa, A.-R. et al. (2015) ‘Amniocentesis for the detection of congenital toxoplasmosis: results from the nationwide Austrian prenatal screening program’, Clin. Microbiol. Infect., 21(2), pp. 191.e1–8. doi:https://doi.org/10.1016/j.cmi.2014.09.018. · doi:10.1016/j.cmi.2014.09.018
- Radke, 2018, Evaluation of current and emerging antimalarial medicines for inhibition of Toxoplasma gondii growth in Vitro, ACS Infect. Dis., 4, 1264, 10.1021/acsinfecdis.8b00113 · DOI
- Rajapakse, 2013, Antibiotics for human toxoplasmosis: a systematic review of randomized trials, Pathog. Glob. Health, 107, 162, 10.1179/2047773213Y.0000000094 · DOI
- Ramakrishnan, 2015, The intracellular parasite Toxoplasma gondii depends on the synthesis of long-chain and very long-chain unsaturated fatty acids not supplied by the host cell, Mol. Microbiol., 97, 64, 10.1111/mmi.13010 · DOI
- Rezaei, 2018, A systematic review of Toxoplasma gondii antigens to find the best vaccine candidates for immunization, Microb. Pathog., 126, 172, 10.1016/j.micpath.2018.11.003 · DOI
- Robert-Gangneux, 2014, It is not only the cat that did it: how to prevent and treat congenital toxoplasmosis, J. Infect., 68, S125, 10.1016/j.jinf.2013.09.023 · DOI
- Robert-Gangneux, 2011, The placenta: a main role in congenital toxoplasmosis?, Trends Parasitol., 27, 530, 10.1016/j.pt.2011.09.005 · doi:10.1016/j.pt.2011.09.005
- Robert-Gangneux, 2015, Molecular diagnosis of toxoplasmosis in immunocompromised patients: a 3-year multicenter retrospective study, J. Clin. Microbiol., 53, 1677, 10.1128/JCM.03282-14 · doi:10.1128/jcm.03282-14
- Robert-Gangneux, 2018, Toxoplasmosis in transplant recipients, Europe, 2010–2014, Emerg. Infect. Dis., 24, 1497, 10.3201/eid2408.180045 · DOI
- Romand, 1993, In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii, Antimicrob. Agents Chemother., 37, 2371, 10.1128/AAC.37.11.2371 · doi:10.1128/aac.37.11.2371
- Rothova, 1993, Therapy for ocular toxoplasmosis, Am J. Ophthalmol., 115, 517, 10.1016/S0002-9394(14)74456-3 · DOI · Paper page
- Rutaganira, 2017, Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii, J. Med. Chem., 60, 9976, 10.1021/acs.jmedchem.7b01192 · DOI
- Saba, 1993, Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS, Eur. J. Clin. Microbiol. Infect. Dis., 12, 853, 10.1007/BF02000407 · doi:10.1007/bf02000407
- Schmidt, 2006, The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999–2002, Arch. Dis. Child., 91, 661, 10.1136/adc.2004.066514 · DOI
- Schuster, 2006, In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri, J. Eukaryot. Microbiol., 53, 121, 10.1111/j.1550-7408.2005.00082.x · DOI
- Shubar, 2008, A new combined flow-cytometry-based assay reveals excellent activity against Toxoplasma gondii and low toxicity of new bisphosphonates in vitro and in vivo, J. Antimicrob. Chemother., 61, 1110, 10.1093/jac/dkn047 · doi:10.1093/jac/dkn047
- Signorell, 1996, Cord blood screening for congenital toxoplasmosis in northwestern Switzerland, 1982–1999, Pediatr. Infect. Dis. J., 25, 123, 10.1097/01.inf.0000195542.43369.96 · DOI
- Silva, 2017, Genetic polymorphisms and phenotypic profiles of sulfadiazine-resistant and sensitive Toxoplasma gondii isolates obtained from newborns with congenital toxoplasmosis in Minas Gerais, Brazil, PLoS One, 12, 10.1371/journal.pone.0170689 · DOI
- Spalenka, 2018, Discovery of new inhibitors of Toxoplasma gondii via the pathogen box, Antimicrob. Agents Chemother., 62, 10.1128/AAC.01640-17 · DOI
- Tan, 2010, Monoclonal antibodies against nucleoside triphosphate hydrolase-II can reduce the replication of Toxoplasma gondii, Parasitol. Int., 59, 141, 10.1016/j.parint.2009.12.007 · DOI
- Teimouri, 2018, Anti-Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain, Int. J. Nanomedicine, 13, 1341, 10.2147/IJN.S158736 · DOI
- Thiébaut, 2007, Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients’ data, Lancet, 369, 115, 10.1016/S0140-6736(07)60072-5 · DOI · Paper page
- Torre, 1998, Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian collaborative study group, Antimicrob. Agents Chemother., 42, 1346, 10.1128/AAC.42.6.1346 · doi:10.1128/aac.42.6.1346
- Torres, 1997, Atovaquone for salvage treatment and suppression of Toxoplasmic encephalitis in patients with AIDS, Clin. Infect. Dis., 24, 422, 10.1093/clinids/24.3.422 · doi:10.1093/clinids/24.3.422
- Valentini, 2009, Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy, Eur. J. Clin. Microbiol. Infect. Dis., 28, 297, 10.1007/s10096-008-0612-5 · doi:10.1007/s10096-008-0612-5
- Vidadala, 2016, Development of an orally available and central nervous system (CNS) penetrant Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitor with minimal human ether-a-go-go-related gene (hERG) activity for the treatment of toxoplasmosis, J. Med. Chem., 59, 6531, 10.1021/acs.jmedchem.6b00760 · DOI
- Villena, 1998, Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997. Reims toxoplasmosis group, Scand. J. Infect. Dis., 30, 295, 10.1080/00365549850160963 · DOI
- Wallon, M. et al. (2013) ‘Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years’, Clin. Infect. Dis., 56(9), pp. 1223–1231. doi:https://doi.org/10.1093/cid/cit032. · DOI · Paper page
- Wang, 2017, Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis, Lancet HIV, 4, e177, 10.1016/S2352-3018(17)30005-X · DOI · Paper page
- Webster, 2012, Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier, Am. J. Trop. Med. Hyg., 87, 715, 10.4269/ajtmh.2012.12-0100 · doi:10.4269/ajtmh.2012.12-0100
- Wei, 2015, A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans, PLoS One, 10, 10.1371/journal.pone.0138204 · doi:10.1371/journal.pone.0138204
- Wilson, 1980, Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection, Pediatrics, 66, 767, 10.1542/peds.66.5.767 · DOI · Paper page
- Yap, 2000, Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii, J. Immunol., 165, 628, 10.4049/jimmunol.165.2.628 · DOI · Paper page
- Yarovinsky, 2014, Innate immunity to Toxoplasma gondii infection, Nat. Rev. Immunol., 14, 109, 10.1038/nri3598 · DOI · Paper page
- You, 2017, Silver nanoparticle loaded collagen/chitosan scaffolds promote wound healing via regulating fibroblast migration and macrophage activation, Sci. Rep., 7, 10.1038/s41598-017-10481-0 · DOI · Paper page
Cited by
Epidemiology, Pathophysiology, Diagnosis, and Management of Cerebral Toxoplasmosis
Elsheikha, H. M., Marra, C. M., & Zhu, X.-Q. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-19 · Cited by 262
Toxoplasma gondii vaccine candidates: a concise review
Mamaghani, A. J., Fathollahi, A., Arab-Mazar, Z., kohansal, K., Fathollahi, M., Spotin, A., Bashiri, H., & Bozorgomid, A. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-02998-9 · Cited by 51
Promising drug targets and compounds with anti-Toxoplasma gondii activity
Silva, M. D., Teixeira, C., Gomes, P., & Borges, M. (2021) · Microorganisms · doi:10.3390/microorganisms9091960 · Cited by 44
Sun, H.-C., Deng, P.-M., Fu, Y., Deng, J.-H., Xie, R.-H., Huang, J., Qi, M., & Shi, T.-Y. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1209755 · Cited by 22
Metadata
- Authors
- Konstantinovic, N., Guegan, H., Stäjner, T., Belaz, S., & Robert-Gangneux, F.
- Venue
- Food and Waterborne Parasitology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 15
- Pages
- e00036
- ISSN
- 2405-6766 (ISSN-L)
- OpenAlex
- W2926432634
- Cited by
- 218
- References
- 1
- FWCI
- 13.39
- Type
- journal article
- Language
- en
- Update notices
- erratum (2020-12-01)
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of toxoplasmosis: Current options and future perspectives. https://app.cochat.ai/papers/10.1016/j.fawpar.2019.e00036
- The paper
- Konstantinovic, N., Guegan, H., Stäjner, T., Belaz, S., & Robert-Gangneux, F. (2019). Treatment of toxoplasmosis: Current options and future perspectives. Food and Waterborne Parasitology. https://doi.org/10.1016/j.fawpar.2019.e00036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.